Results 11 to 20 of about 2,906,691 (234)

Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin

Nature Communications, 2022
In patients with colorectal peritoneal metastases scheduled for cytoreductive surgery, accurate preoperative estimation of tumor burden and subsequent intraoperative detection of all tumor deposits remains challenging.
J. D. de Gooyer, F. M. Elekonawo, A. Bremers, O. Boerman, E. Aarntzen, P. D. de Reuver, I. Nagtegaal, M. Rijpkema, J. D. de Wilt   +8 more
semanticscholar   +1 more source

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study

World Journal of Surgical Oncology, 2022
Background Cytoreductive surgery followed by systemic chemotherapy is the standard of treatment in advanced ovarian cancer where feasible. Neoadjuvant chemotherapy (NACT) followed by surgery is applicable where upfront cytoreductive surgery is not ...
E. Miralpeix, J. Sole-Sedeno, C. Rodriguez-Cosmen, Á. Taus, Maria D. Muns, Berta Fabregó, G. Mancebo   +6 more
semanticscholar   +1 more source

Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)

Journal of Gynecologic Oncology, 2022
Objective To investigate the health-related quality of life (HRQOL) related to hyperthermic intraperitoneal chemotherapy (HIPEC) following primary or interval cytoreductive surgery for primary ovarian cancer. Methods Between 2010 and 2016, a total of 184
J. Kim, Dong-eun Lee, Yumi Lee, H. I. Ha, Y. Chang, Suk-Joon Chang, Sang-Yoon Park, M. Lim   +7 more
semanticscholar   +1 more source

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +4 more sources

Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis

Journal of Clinical Oncology, 2021
PURPOSE The survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer was studied. METHODS We identified published studies from 1983 to 2021 following our inclusion criteria from MEDLINE, EMBASE, and ...
M. Baek, E. Park, H. I. Ha, S. Park, M. Lim, C. Fotopoulou, R. Bristow   +6 more
semanticscholar   +1 more source

The current role of secondary cytoreductive surgery for recurrent ovarian cancer

Frontiers in Oncology, 2022
Ovarian cancer represents worldwide the second most frequent and the most fatal gynecological malignancy, with approximately two thirds of the patients presenting with advanced disease. Cytoreductive surgery, primary or after neoadjuvant chemotherapy, in
E. de Bree, Dimosthenis Michelakis, Elisavet Anagnostopoulou   +2 more
semanticscholar   +1 more source

Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer

Scientific Reports, 2021
The standard treatment for advanced ovarian cancer (AOC) is cytoreduction surgery and adjuvant chemotherapy. Tumor volume after surgery is a major prognostic factor for these patients.
A. Llueca, M. Climent, J. Escrig, Paula Carrasco, A. Serra, L. R. G. V. A. K. K. M. N. C. A. I. C. J. P. E. A. R. Gomez-Quiles Játiva Cebrian Bosso Villarin Maiocch, L. Gómez-Quiles, R. Jativa, G. Cebrián, V. Bosso, A. Villarin, K. Maiocchi, K. Delgado-Barriga, M. Rodrigo-Aliaga, N. Ruiz, C. Herrero, A. Francés, I. Beato, C. Ferrer, J. P. Aracil, E. Boldo, A. Boldó, R. Adell   +22 more
semanticscholar   +1 more source

Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]

, 2015
BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio, Biacchi, Daniele, Cardi, Maurizio, DI GIORGIO, Angelo, Mingarelli, Valentina, Musio, Daniela, Sammartino, Paolo, Sibio, Simone, Sollazzo, BIANCA MARIA   +8 more
core   +2 more sources

Prognostic factors influencing infectious complications after cytoreductive surgery and HIPEC. Results from a tertiary referral center [PDF]

, 2019
Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application.
Carbonari, Ludovica, Cardi, Maurizio, D'Agostino, Claudia, Fonsi, Giovanni Battista, Francesco Di Marzo,, Francesco, Lefoche, LA TORRE, Giuseppe, Sammartino, Paolo, Sibio, Simone   +8 more
core   +1 more source

Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival.

Journal of Clinical Endocrinology and Metabolism, 2021
CONTEXT The role of cytoreduction of adrenocortical carcinoma (ACC) remains poorly understood. OBJECTIVE To analyze the impact of cytoreductive surgery of the primary tumor in patients with metastatic ACC.
V. Srougi, I. Bancos, Marilyne Daher, Jeffrey E. Lee, P. Graham, J. Karam, A. Henriquez, T. Mckenzie, A. Sada, I. Bourdeau, Jonathan Poirier, A. Vaidya, Tiffany Abbondanza, Collen M Kiernan, S. Rao, O. Hamidi, Nirupa Sachithanandan, A. Hoff, J. Chambo, M. Almeida, M. Habra, M. C. Fragoso   +21 more
semanticscholar   +1 more source